Vaccination of Malignant Glioma Patients with Peptide-pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-cell Infiltration1

John S. Yu, Christopher J. Wheeler, Paul M. Zeltzer, Han Ying, Divina N. Finger, Paul K. Lee, William H. Yong, Francesca Incardona, Reid C. Thompson, Mary S. Riedinger, Wexuan Zhang, Robert M. Prins,2 and Keith L. Black3


Abstract

In this Phase I trial, patients' peripheral blood dendritic cells were pulsed with peptides eluted from the surface of autologous glioma cells. Three biweekly intradermal vaccinations of peptide-pulsed dendritic cells were administered to seven patients with glioblastoma multiforme and two patients with anaplastic astrocytoma. Dendritic cell vaccination elicited systemic cytotoxicity in four of seven tested patients. Robust intratumoral cytotoxic and memory T-cell infiltration was detected in two of four patients who underwent reoperation after vaccination. This Phase I study demonstrated the feasibility, safety, and bioactivity of an autologous peptide-pulsed dendritic cell vaccine for patients with malignant glioma.

Introduction

Despite aggressive multimodality therapy, the prognosis for patients with malignant glioma is poor. The current treatment of glioblastoma, GBM,4 which consists of surgical resection followed by radiation therapy and/or chemotherapy, results in a median survival of less than 1 year (1). Glioblastoma cells are known to be poor antigenpresenters to the immune system, in part because of down-regulation of B7 costimulatory molecules required for direct tumor cell activation of T cells (2, 3). To induce an antitumor immune response against glioblastomas, professional APCs may be needed to efficiently internalize, process, and present glioma antigens to T cells (4–6). In the present study, DCs were used for antigen presentation of glioma antigens to circumvent the inability of gliomas to directly induce a cytotoxic T-cell response. DCs are potent “professional” APCs. Recent studies have demonstrated the use of tumor peptide-pulsed DCs to successfully treat murine models of metastatic intracranial tumor (7) and glioma (8, 9). This report describes the response of patients with malignant glioma to peptide-pulsed DC vaccination. In this Phase I trial, patients' peripheral blood stem cells were expanded ex vivo into DCs and pulsed with peptides eluted from the surface of cultured autologous brain tumor cells. Three biweekly intradermal vaccinations of peptide-pulsed DCs were administered to seven patients with GBM and two patients with anaplastic astrocytoma. Immunological monitoring end points were systemic cytotoxicity and, when clinically indicated, intracranial T-cell infiltration. Clinical end points were toxicity and survival. We speculated that DC vaccination would generate antigen-specific T cells. Indeed, DC vaccination elicited significant systemic T-cell cytotoxicity against autologous glioma tumor cells in four of seven patients. We sought to determine whether these cytotoxic T cells were trafficking to intracranial tumor. Two of four patients who underwent reoperation for new areas of gadolinium enhancement on magnetic resonance imaging (consistent with tumor, radiation necrosis, or inflammation) demonstrated a robust cytotoxic (CD8+) and memory (CD45RO+) T-cell infiltration in areas of intracranial tumor. This Phase I study demonstrates the feasibility, safety, and antitumor immune activity of an autologous peptide-pulsed DC vaccine for malignant glioma. Systemic cytotoxicity and intracranial cytotoxic T-cell infiltration were elicited in a subset of patients, and this biological activity may be associated with prolonged survival in patients with glioblastoma.

Materials and Methods

Patient Population. Inclusion criteria were a Karnofsky score of 60 or greater, lowest possible maintenance dose of glucocorticoid therapy, no allergy to components of the DCs, and normal baseline hematological parameters (within 1 week before first vaccination): hemoglobin >9.9 g/dl; total granulocyte count >1000/μl; platelet count >60,000/μl; BUN <30 mg/dl; creatinine <2 mg/dl; alkaline phosphatase; aspartate aminotransferase less than twice the upper limit of normal; and a prothrombin time and activated partial thromboplastin time no greater than 1.4 times control, unless therapeutically warranted.

Exclusion criteria included pregnancy, severe pulmonary, cardiac, or other systemic disease associated with an unacceptable anesthetic or operative risk, presence of an acute infection requiring active treatment, and history of an autoimmune disorder or prior history of other malignancies, excluding basal cell carcinoma and benign tumors. Patients were required to use a medically accepted form of birth control during the study.

There were nine patients enrolled in this Phase I study: five women and four men with an age range from 28 to 77 years of age (mean, 49 years; see Table 1). Patients with verified histological diagnoses of newly diagnosed anaplastic astrocytoma (two patients) or GBM (seven patients) were eligible for this study. After surgical resection of their tumor, patients were required to complete a course of external beam radiation therapy (standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed). All of the patients were off steroids at the time of vaccination. The 7 study patients with GBM were included in a survival analysis and compared with 42 patients in the control group. Their mean age was 55.9 ± 14.5 years, and 50% were male. All of the patients had tumor pathology consistent with GBM, had undergone surgical resection at our institution within the past 2 years, and had completed a course of radiation therapy (60 Gy as above).

Autologous Tumor Culture. Tumor samples from surgical resection were processed for tissue culture by mincing with scissors and passing through metal meshes of decreasing pore size. The cell suspension was then plated onto tissue culture flasks and grown in DMEM/F10 (Irvine Scientific, Santa Ana, CA) plus 10% FCS (Irvine Scientific) and 1% penicillin/streptomycin (Life Technologies, Inc.). The adherent cell population was retained and passaged until 105 cells were generated.

1. Received 5/15/00; accepted 12/13/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

2. Supported in part by National Institute of Health Grant N5022/2 (to J.S.Y.)

3. Present address: Department of Anatomy, Medical College of Virginia, Richmond, Virginia 23229.

4. The abbreviations used are: GBM, glioblastoma multiforme; APC, antigen-presenting cells; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin; DTH, delayed type hypersensitivity.

Downloaded from cancerres.aacrjournals.org on April 13, 2017. © 2001 American Association for Cancer Research.
Methods for Tumor Antigen PCR. Total tumor cell RNA was isolated using TriZol RNA isolation kit (Life Technologies, Inc.) from cultured autologous glioma cells from nine study patients. For cDNA synthesis, 10 µg of total RNA were digested with 2 µl of DNase I (Ambion) to remove genomic DNA. The RNA was transcribed with cDNA synthesis reagents (Life Technologies, Inc.) in total volume of 50 µl with the use of oligo(dt) (Life Technologies, Inc.). For PCR, 1 µl/50 µl of the synthesized cDNA was used with 10 pmol of primers, 1.5 mm MgCl₂, 200 µM deoxynucleotide triphosphates, and 0.1 µl of Platinum Taq polymerase (Life Technologies, Inc.). Thermal cycler parameters included 5 min at 95°C initiation and 35 cycles involving denaturation at 95°C for 30 s, annealing at 58°C (for MAGE-1 and β-actin) or 52°C (for gp100 and TRP-2) for 30 s, and extension at 72°C for 1 min. Primers used for PCR are as follows: primers for MAGE-1, forward, 5'-GCTGCTGCCCCTGACGAGAG-3'; reverse, 5'-AGGTGCAGTGCTTATGACTT-3'; primers for gp100, forward, 5'-TGAGGTGTGGAGAGAGGAAG-3'; reverse, 5'-GTGGGATATGAGGAAACAG-3'; primers for β-actin, forward, 5'-ATATCCGGACACACCTC-3'; reverse, 5'-CTTCTCCTTAATGCACGACCC-3'.

Isolation of Tumor-specific MHC-I-associated Peptides. MHC-I-associated peptides were enriched by traceless accl be as described previously (10). Briefly, 10⁶ glioma cells were removed from tissue culture plates by incubation with 2 ml EDTA at room temperature, followed by three washes with HBSS. The cells were resuspended in 10 ml of citrate-phosphate buffer (pH 3.2) to dissociate peptides from surface MHC-I, triturated gently, and centrifuged for 5 min at 1000 rpm. The supernatant was then collected and concentrated by passage through Sep Pak C18 columns, aliquotted, and frozen at °80°C. Before patient vaccination, tumor peptide was tested in the Limulus Amoebocyte Lysate assay (BioWhittaker Inc., Walkersville, MD) for endotoxin contamination, for aerobic, anaerobic, and fungal culture, and by Gram's stain before administration to the patient.

Preparation of Autologous DCs. Venous blood (20 ml) was drawn from patients on days 7, 14, and 21 (day 0 = first vaccination). The anticipated yield was 10⁶ APCs/20 ml whole blood. In addition, 50 ml of blood was drawn on day 14 to obtain autologous serum (15 ml) for each of three APC cultures. APCs were isolated from whole blood by Ficoll-Hypaque centrifugation, washed three times in PBS, and plated at a concentration of 5 x 10⁶ cells/ml in complete medium consisting of RPMI 1640 (Life Technologies, Inc.) with 10% autologous heat-inactivated serum, 1% gentamicin, and 0.01 M HEPES buffer. After 2 h at 37°C, nonadherent cells were removed by washing with warm complete medium. To generate autologous DCs, adherent APCs were cultured in complete medium for 7 days in the presence of recombinant human GM-CSF (800 units/ml; clinical grade; Immunex Corp., Seattle, WA) and recombinant human IL-4 (500 units/ml; R&D Systems, Inc., Minneapolis, MN).

Preparation and Administration of Autologous DCs Pulsed with Tumor-specific MHC-I Peptides. On the days before each of the three DC vaccinations (days 1, 13, and 27), DC cultures were incubated with citrate-phosphate buffer [0.131 M Na₂HPO₄ (pH 3.0)] for 1 min to strip endogenous peptides from MHC-I molecules. Cells were then washed in RPMI 1640 with 10% autologous patient serum supplemented with 50 µg/ml autologous tumor-specific MHC-I peptides. The DCs were cultured overnight with these peptides on a tissue rotator to facilitate their interaction. Patients received 10⁷ tumor-specific MHC-I peptide-pulsed DCs s.c. in 0.1–0.2 ml saline in the deltoid region. Three vaccinations at 2-week intervals were administered to each patient.

DC Phenotypic Evaluation. After 7-day maturation in GM-CSF and IL-4, DCs were harvested from flasks. Cells were resuspended in RPMI-10% human AB medium and irradiated with 2500 rad in a Cesium-sion irradiator. The remaining cells were resuspended in PBS containing fetal bovine serum (2% v/v) and stained with anti-CD14 FITC, anti-HLA-DR phycoerythin for MHC Class II, and biotinylated anti-CDS6 antibodies for B7-1(PharMingen, San Diego, CA). Species and isotype-matched monoclonal antibodies were used as controls.

DC Functional Assay. For the functional assay, irradiated DCs were resuspended in RPMI-10% human AB serum at 2 x 10⁵ cells/ml. Allogeneic PBMC (10,000) were mixed with limiting dilutions of DCs. PHA (5 µg/ml) was added to separate PBMC cultures as a positive control. RPMI-10% AB medium alone was added to separate PBMC cultures as a negative control. All of the cultures were established in triplicate. PBMC under the above conditions were incubated for 6 days in a 37°C/5% CO₂ incubator. [3H]thymidine (1 µCi/well) was added for the final 18 h. Cells were harvested with a 96-well harvester (Tomtec, Hamden, CT), and cpm were determined on a Microbeta 1450 Trilux liquid scintillation counter (Wallac, Gaithersburg, MD).

CTL Precursor Assay Method. For stimulation, 50 µl of irradiated tumor cells at 1 x 10⁷/ml were plated in RPMI 1640 with 10% heat-inactivated autologous serum with autologous 100 ml of PBMC at 1 x 10⁵/ml. IL-2 was added to give a final concentration of 1000 units/ml, and the plate was incubated at 37°C in 5% CO₂ for 14 days. Cultures were fed on day 3 by removing 50 µl of supernatant and replacing it with medium with IL-2 (4000 units/ml), and on day 7, 100 µl of supernatant was removed and replaced with 100 µl (10,000) autologous irradiated tumor cells at 1 x 10⁵/ml. Autologous tumor cell targets were labeled for 48 h with [3H]thymidine (2.5 µCi/ml). On day 14, targets were trypsinized, washed twice in HBSS, and resuspended at 10,000 cells/ml. Cells (100 µl) were transferred from the coculture plates and added to an empty 96-well plate. Labeled target cells (1 x 10⁵/ml) were added on top of the stimulated PBMCs and resuspended in RPMI-10% human AB serum. The plate was centrifuged at 1000 x g for 3 min and incubated at 37°C for 5 h. Maximum release was assessed in triplicate wells containing 10,000 target cells and 5% SDS in H₂O and DNase 1 (Roche, Indianapolis, IN) at 20 units/ml final concentration for 10 min. The cells were harvested with a cell harvester (Wallac), and cpm were determined on a Microbeta 1450 Trilux liquid scintillation counter (Wallac). The first two patients were analyzed using a CTL precursor assay to quantitate cytotoxic precursor frequency independent of in vitro stimulation effects. The inability to grow sufficient numbers of tumor cells to calculate precursor frequencies necessitated adoption of non-quantitative bulk CTL assays for the remainder of the patients.

Bulk Cytotoxic T-cell Assay. CTL activity was tested by JAM assay (11). Patients four through eight grew sufficient numbers of tumor cells (2 x 10⁷ cells) to complete JAM assays and were evaluated. PBMC for pretreatment and after treatment time points were thawed, washed twice by centrifugation, and counted. The concentration was adjusted to 8 x 10⁶/ml in RPMI 1640 medium containing heat-inactivated human AB serum (10%), nonessential amino acids (1%), penicillin/streptomycin (1%), and 1 µM HEPES buffer (1%). PBMC were stimulated with allogeneic PBMC (irradiated with 2,000 rad) or with autologous cultured tumor cells (irradiated with 11,000 rad; 1 x 10⁵/ml) for 6 days in RPMI-5 and recombinant human IL-2 (20 units/ml). Tumor or allogeneic PHA blasts (1 x 10⁵/ml) were labeled as targets in 5 µCi/ml

Table 1: Patient characteristics

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Tumor pathology</th>
<th>Age</th>
<th>Prevacine Rx</th>
<th>After vaccination Rx</th>
<th>Adverse events</th>
<th>Survival (days)</th>
<th>Time to progression (days)</th>
<th>Time of additional surgery</th>
<th>Intratumoral T cells</th>
<th>PeripheralCTL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AA®</td>
<td>28</td>
<td>Hydroxyurea</td>
<td>PolyIC</td>
<td></td>
<td>632</td>
<td>259</td>
<td>264</td>
<td>Negative</td>
<td>Positive</td>
</tr>
<tr>
<td>2</td>
<td>GBM</td>
<td>51</td>
<td>Reoperation</td>
<td></td>
<td></td>
<td>D381</td>
<td></td>
<td></td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>GBM</td>
<td>48</td>
<td>Gliadel</td>
<td></td>
<td>Fever, nausea</td>
<td>618</td>
<td>D463</td>
<td>216</td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>GBM</td>
<td>49</td>
<td>Reoperation, SRT</td>
<td></td>
<td></td>
<td>550</td>
<td></td>
<td></td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>GBM</td>
<td>30</td>
<td>PolyIC</td>
<td></td>
<td></td>
<td>455</td>
<td></td>
<td></td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>GBM</td>
<td>59</td>
<td>Reoperation, SRT</td>
<td></td>
<td></td>
<td>574</td>
<td></td>
<td></td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>GBM</td>
<td>42</td>
<td></td>
<td></td>
<td></td>
<td>315</td>
<td></td>
<td></td>
<td>Pre-existing</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>GBM</td>
<td>55</td>
<td>Reoperation, SRT</td>
<td></td>
<td></td>
<td>74/222</td>
<td>81/232</td>
<td></td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>GBM</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td></td>
<td></td>
<td>Positive</td>
<td></td>
</tr>
</tbody>
</table>

* AA, anaplastic astrocytoma; Gliadel, intracranial 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; Poly IC, nonspecific immunotherapy; SRT, stereotactic radiation therapy; D, time of death.
of nine patients demonstrated gp100 expression (Fig. 1A). Patients expressed MAGE-1 in cultured glioma cells (Fig. 1B). Total tumor cell RNA was isolated and reverse transcribed into cDNA. PCR was performed using gene-specific primers for MAGE-1, MAGE-2, MAGE-3, MAGE-4, B7-1, and B7–1. Allogenic proliferation assays confirmed that the DCs isolated were functional (Fig. 2A) and sufficient numbers of functional DCs were isolated in all of the patients in this clinical trial (10^6 DCs/vaccination). These DCs were cocultured with autologous tumor peptide, washed, and administered to patients three times over the course of 6 weeks.

**Isolation and Characterization of DCs.** Mononuclear cells were isolated by Ficoll gradient centrifugation and differentiated into DCs in the presence of IL-4 and GM-CSF. These professional APCs expressed high levels of MHC class II and of costimulatory molecule B7-1 and the absence of markers for mature monocytes (CD14; data not shown). In all of the patients, greater than 70% of the cells exhibited a DC phenotype: HLA-DR^+^, B7–1^+^, and CD14^−^. Allogenic proliferation assays confirmed that the DCs isolated were functional (Fig. 2A) and sufficient numbers of functional DCs were isolated in all of the patients in this clinical trial (10^6 DCs/vaccination). These DCs were cocultured with autologous tumor peptide, washed, and administered to patients three times over the course of 6 weeks.

**Safety of Autologous DC Administration.** There were no serious adverse events or clinical or radiological evidence of autoimmune reaction in any patient (Table 1). Patient 3 developed a mild fever (100°F) lasting several hours after vaccination. The same patient also developed nausea and vomiting several weeks later. Patient 5 developed palpable supraclavicular, axillary, and inguinal lymph nodes 1 week after the first vaccination, which persisted for 2 months.

**Development of Systemic Cytotoxicity.** One goal of this clinical trial was to determine whether ex vivo maturation of DCs and exposure of DCs to a MHC-I-associated tumor antigen from autologous cultured glioma cells could induce an immune response against malignant gliomas. Cytotoxicity directed toward autologous tumor cells was assessed in PBMC from patients’ pre-vaccination, 1 week after each vaccination, and 6 and 12 weeks after the last vaccination. Of seven patients that were evaluated, four demonstrated enhanced cytotoxic T-cell activity after DC vaccination. In all of the patients who developed cytotoxic T-cell activity, cytotoxicity was sustained through the last time point, 3 months after the last vaccination (Fig. 2B). In two patients (2 and 4), cytotoxicity developed 12 weeks after the third DC vaccination. Patients 7 and 8 demonstrated cytotoxicity before and after vaccination. Patient 1 had no discernible CTL activity before or after vaccination.

**Intracranial Infiltration of T Cells after Vaccination.** Four patients who developed apparent tumor progression as suggested by new CT scans exhibited a DC phenotype: HLA-DR^+^, B7–1^+^, and CD14^−^. Allogenic proliferation assays confirmed that the DCs isolated were functional (Fig. 2A) and sufficient numbers of functional DCs were isolated in all of the patients in this clinical trial (10^6 DCs/vaccination). These DCs were cocultured with autologous tumor peptide, washed, and administered to patients three times over the course of 6 weeks.

**Results**

Characterization of Autologous Tumor Cells. Patients’ tumors were resected, and the surgical tissue was used to establish autologous glioma cell lines. Cells were passaged 7–12 times to obtain approximately 10^8 cells. MHC-I-associated peptides derived from these lines were enriched through acid elution. Karyotype analysis was performed on seven autologous tumor cultures from seven study patients. Six patients had glioblastoma, and one patient had anaplastic astrocytoma. At least 20 cells were analyzed from the cultures of the cells of these patients. Of the six glioblastoma patients, five patients had abnormal karyotype in all of the cells studied. Four of these karyotypes displayed gain of chromosome 7. One patient with glioblastoma and one patient with anaplastic astrocytoma demonstrated normal karyotypes. Cell lines from nine study patients were characterized by specific fragmentation of [3H]-labeled DNA in autologous tumor targets at various E:T ratios using the JAM test. The graph depicts CTL activity from patient 5 before vaccination, as well as 6 weeks (A) and 12 weeks (B) after the last of three DC/tumor peptide administrations.

**Safety of Autologous DC Administration.** There were no serious adverse events or clinical or radiological evidence of autoimmune reaction in any patient (Table 1). Patient 3 developed a mild fever (100°F) lasting several hours after vaccination. The same patient also developed nausea and vomiting several weeks later. Patient 5 developed palpable supraclavicular, axillary, and inguinal lymph nodes 1 week after the first vaccination, which persisted for 2 months.

**Development of Systemic Cytotoxicity.** One goal of this clinical trial was to determine whether ex vivo maturation of DCs and exposure of DCs to a MHC-I-associated tumor antigen from autologous cultured glioma cells could induce an immune response against malignant gliomas. Cytotoxicity directed toward autologous tumor cells was assessed in PBMC from patients’ pre-vaccination, 1 week after each vaccination, and 6 and 12 weeks after the last vaccination. Of seven patients that were evaluated, four demonstrated enhanced cytotoxic T-cell activity after DC vaccination. In all of the patients who developed cytotoxic T-cell activity, cytotoxicity was sustained through the last time point, 3 months after the last vaccination (Fig. 2B). In two patients (2 and 4), cytotoxicity developed 12 weeks after the third DC vaccination. Patients 7 and 8 demonstrated cytotoxicity before and after vaccination. Patient 1 had no discernible CTL activity before or after vaccination.

**Intracranial Infiltration of T Cells after Vaccination.** Four patients who developed apparent tumor progression as suggested by new CT scans...
CD8+ T cells underwent reoperation subsequent to the third DC vaccination.

Areas of gadolinium enhancement on magnetic resonance imaging demonstrated massive intratumoral infiltration by CD8+ cytotoxic T cells and CD45RO+ memory T cells, as compared with tumor specimens before vaccination (Fig. 3, A–D). There were no CD20+ B cells or CD56+ NK cells detectable before or after vaccination in any patient (data not shown). In contrast, two other patients who underwent reoperation for a recurrent gadolinium-enhancing mass (patients 2 and 4) displayed few infiltrating CD45RO+, CD8+, CD4+, CD20+, or CD56+ cells in surgical specimens taken before or after vaccination (data not shown). Both of these patients died from tumor progression. Similarly, there was no increase in numbers of intratumoral lymphocytes in specimens from four nonvaccinated GBM patients who underwent re-resection. All of the four nonvaccinated patients demonstrated few CD45RO+ and CD8+ T cells from their first surgical specimen, which diminished in number in reoperation specimens (Fig. 3, I and J). There were very few CD20+ B cells in the first and second specimens, and no CD56+ NK cells were detected in either specimen. Thus, enhanced cytotoxic (CD8+) T-cell and memory (CD45RO+) T-cell infiltration appears to be a characteristic of a subset of vaccinated patients who undergo reoperation.

DC Vaccination Is Associated with Prolonged Survival. A further objective of this study was to determine the clinical response to DC vaccination. There were 7 patients in the study group and 42 patients in the control group with newly diagnosed GBM treated at our institution. Control patients underwent craniotomy by the same surgeons as the study group and external beam radiation therapy of 60 Gy with or without chemotherapy. They met all of the inclusion criteria of the DC immunotherapy trial including Karnofsky score but were treated before the trial opening (within 2 years) or chose not to participate. There were no statistically significant differences between the study and control groups for age (54.4 ± 11.3 years, study group, versus 55.9 ± 14.5 years, control group; P = 0.79), gender (42% male, study group, versus 50% male, control group; P = 0.77), and percentage of patients with gross total removal of gadolinium-enhancing tumor (71%, study group, versus 58%, control group; P = 0.68). The median survival times for the study and control groups were 455 and 257 days, respectively.

Discussion

Previous immunotherapeutic treatments for brain tumors have focused on passive, adoptive, and nonspecific strategies and have yielded unclear benefits (12). The active immunotherapy strategy using DC vaccinations reported here could be more effective against malignant glioma than previous strategies. Active immunotherapy requires the administration of an antigenic target. MHC-I-associated peptides were eluted from cultured autologous glioma cells. Cultured autologous tumor cells were characterized for three tumor-associated antigens: TRP-1, MAGE-1, and gp100. Melanocytes and glial cells are embryologically derived from neural ectoderm. Malignant transformed counterparts have been shown to share common antigens. Melanoma-associated antigen mRNA (13) and protein (14) have been described on glioma cells. Eight out of nine cell lines derived from study patients demonstrated expression of at least one of these tumor-associated antigens. The expression of tumor-associated antigens on autologous tumor cell cultures suggests that these lines are derived from glialoma rather than from normal neural cells or fibroblasts, because these tissues rarely or never express melanoma-associated antigens (13). Abnormal karyotype was seen in five of seven cultured cell lines from study patients, further suggesting that these cells were tumor cells. The frequent expression of these tumor-associated antigens on glioma-derived cell lines points to potential antigenic targets on these tumors.

One goal of this clinical trial was to determine whether ex vivo maturation of DCs and exposure of DCs to a MHC-I-associated tumor antigen from autologous cultured glioma cells could induce an immune response against glioma tumor cells. That four of seven tested
patients in this pilot trial have shown cytotoxic T cell-mediated immunological responses after peptide-pulsed DC vaccination supports the role of DC vaccination in generating specific immunity. The relationship between peripheral CTL activity and tumor rejection has not been unequivocally established by the present or by previous trials (15–18).

It was not known whether peripheral cytotoxic T cells would reach their intracranial target after DC vaccination. In some immunotherapy trials, systemic cytotoxic responses have failed to prevent tumor growth in the central nervous system (19, 20). We observed a dramatic intratumoral infiltration of CD45RO+ memory and CD8+ cytotoxic T cells after vaccination in two of four patients who had undergone reoperation for gadolinium enhancement on magnetic resonance imaging which is suggestive of recurrent tumor, whereas nonvaccinated patients exhibited no similar infiltration. Thus, we demonstrate that DC vaccination can induce intra-glioma T-cell infiltration despite the immunologically privileged status of the central nervous system. All of the four patients that underwent reoperation demonstrated either preexisting or new systemic cytotoxicity in vitro. The study of tumor expression of immunosuppressive cytokines or cell surface markers may elucidate factors that differentiate patients who will respond to systemic cytotoxicity.

The presence of CD8+ T cells and absence of CD20+ B cells in intracranial tumor of vaccinated patients is consistent with the initiation of a Th1- rather than a Th2-mediated response by peptide-pulsed DCs, although other alternatives include preferential migration/survival of T cells. Intracranial CD8+ infiltration has been associated with vaccination in active immunotherapy models in mice (9, 21). The robust intratumoral infiltration of CD45RO+ T cells suggests vaccine-mediated induction of activated T cells with specific homing and/or in situ expansion properties. In a DC immunotherapy trial for melanoma, CD45RO+ memory T cells were shown to strongly infiltrate DTH sites, as well as metastases in regression. In addition, significant CD8+ infiltration was noted in regressing metastases. In a separate clinical trial, vaccination of renal cell carcinoma patients with tumor cell–DC hybrids demonstrated DTH sites that were infiltrated by CD8+ cells. Therefore, the intracranial cellular response of patients with malignant glioma mirrors the peripheral response noted in regressing melanoma tumors and in DTH sites of renal cell carcinoma patients after DC vaccination. The absence of both B and NK cell tumor infiltration in the present trial suggests that such effects are relatively limited to the T-cell compartment. This suggests that DCs in this study may preferentially activate antigen-specific T cells, rather than NK cells, as described in distinct in vitro studies (22).

DC vaccination of patients with glioma appears to be safe and not associated with autoimmunity. In this Phase I trial, DC vaccinations were well tolerated. Mild toxicities included transient fever, nausea, and vomiting in one patient and the development of palpable lymph nodes in another patient. To date, with a median follow-up of 455 days, no clinical or radiological features of autoimmune disease were detected in our patients. Clinical trials using DC immunotherapy have been published for four other cancers: lymphoma (15); melanoma (16); prostate cancer (17); and renal cell carcinoma (18). In these DC vaccine studies, mild fever and swelling of an injected lymph node lasting 1–2 days have been reported (16). No other significant adverse events including autoimmunity were reported in trials using DC immunotherapy (15–18) or in animal models of brain tumor therapy with DC vaccination (7–9). Thus, DC vaccination to tumor has not been associated with significant autoimmunity. On the other hand, induction of lethal experimental allergic encephalomyelitis has been described in primates and guinea pigs after vaccination with human glioblastoma tissue (23). Continued evaluation will be necessary to determine if autoimmunity develops from cross-reactivity between brain tumor antigens and normal neural antigens.

Patients with GBM treated with DC vaccination appear to have prolonged survival compared with patients who have had conventional treatment. When study patients were compared with GBM patients who underwent craniotomy with radiation and chemotherapy at our institution, there appeared to be a prolongation in survival of study patients. Although there was no difference in these groups with respect to age, gender, or degree of resection, a selection bias could not be ruled out. Although the number of patients in the study group was small, the survival suggests that this form of active immunotherapy may be a promising approach.

Study patients with glioblastoma were divided into Radiation Therapy Oncology Group (RTOG) recursive partitioning classes (24). This technique allows comparison of series data based on clinical and histological stratification parameters. Three patients with GBM in the study were stratified in RTOG Class III with <50 years of age and Karnofsky performance scores of ≥90. These patients had a median survival of 19.1 months compared with RTOG data of 18 months for this class of 175 patients. Four patients with GBM in the study were stratified in RTOG Class V with >50 years of age, radiotherapy of >54 Gy, and the inability to return to work. This group of patients had a median survival of 11.6 months compared with the RTOG class V patients (n = 395) with a median survival of 9 months. Because of the small number of study patients in each of these classes, statistical analysis could not be performed. The patients in this study, however, exceeded the expected survival according to this analysis. Despite the prolongation of survival in this analysis as well as in the survival analysis compared with GBM patients treated at our institution, the potential for patient selection bias will only be eliminated by a randomized trial.

The association of intracranial CD8+ T-cell infiltration and survival has been established in an active immunotherapy model of intracranial metastasis (25). Active immunotherapy with DCs or tumor vaccines for experimental intracranial glioma have demonstrated an association of CD8+ intratumoral infiltration and prolonged survival (9, 21). The enhanced median survival of patients enrolled in this study suggests that tumor-specific T-cell activation, infiltration, and/or function may prolong the survival of glioma patients. Phase II studies using DC immunotherapy are under way to further elucidate the effects of DC vaccination in patients with malignant gliomas and to confirm its effect on survival. This immunotherapy strategy appears promising as an approach to successfully induce an antitumor immune response and to increase survival in patients with gliomas.

References


Vaccination of Malignant Glioma Patients with Peptide-pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-cell Infiltration


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/3/842

Cited articles This article cites 25 articles, 8 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/3/842.full.html#ref-list-1

Citing articles This article has been cited by 47 HighWire-hosted articles. Access the articles at:
/content/61/3/842.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.